The efficacy of imartinib treatment of glioblastoma was not obvious.

There is still a lack of special treatment for glioblastoma (GBM)studies have found that GBM over-expression of a variety of tyrosine kinase receptors is considered to be an important target for targeted therapyrecent studies have shown that imatinib acts as a inhibition of GBM by inhibiting tyrosine kinase activity, which improves the effectiveness of radiotherapyLisa Sautter of the Radiology Oncology Department at the University of Mannheim Medical Center in Germany, who studies the clinical efficacy of Imatini combined radiotherapy for newly diagnosed and relapsed GBM patients, published online in September 2019Research Methodology The study was a non-random, open-label clinical Phase II trial that included 51 patients with a 0-2 score from the Eastern Oncology Collaboration Group (ECOG) in the United Statesassigned 19 of the newly diagnosed GBM to Group A and 32 recurrences to Group BGroup A patients used imatinib 600mg/d combined radiotherapy (2.5Gy/times, 22 times)Group B patients were given 600 mg/d or retherapy in combination with different doses of Imatinibcan be added to CCNU (100mg/m2, 2 cycles) during imatinib treatment, depending on the progress of the tumorthe median follow-up time after treatment, Group A 4 (0.5 to 30) months, Group B 6.5 (0.3 to 51.5) monthsthe main study endpoint is Progressless Survival (PFS); secondary studies end in safety, adverse reactions, and complications are defined by the Common Terminology Standard (version 2.0) of adverse eventsTotal Lifetime (OS) as an exploratory endpointthe results of the study, the patient's median PFS: Group A 2.8 months (95% CI, 0 to 8.7), Group B 2.1 months (95% CI, 0 to 11.8)median OS: Group A 5.0 (0.8 to 30) months (95% CI, 0 to 24.1), Group B 6.5 (0.3 to 51.5) months (95% CI, 0 to 32.5)A total of 110 adverse reactions of 3-5 occurred inThe main level 3 complications inwere 17 seizures, 11 cases of pneumonia and 7 cases of decreased alertnessConclusion The results show that imartinibic combination radiotherapy did not see significant clinical efficacy in newly diagnosed GBM patients, Imartinib as a single drug treatment patients with relapsed GBM patients also did not see significant resultsCopyright Notice The copyright of works published by the God's Outer Information APP, including but not limited to the copyright of text, pictures and videos, is owned by the organizer/original author and divinated information, and no one may steal any content by direct or indirect means such as adaptation, tailoring, reproduction, reproduction, reproduction, recording, etcwithout the express authorization of outside informationworks authorized by outside god information should be used within the scope of authorization, please indicate the source: god informationif there is a violation, the outside information will reserve the right to further pursue the infringement of legal liabilityoutside the gods welcomeindividuals to forward and share works published under this number.